Advertisement

OncoCyte Corporation OCX

Set alert

Price alert · OCX

All alert types
3.20 0.00 0.00%

At close · Jun 17

2.82 Day range 3.20

52-week range unavailable

YTD
+34.45%
1 year
+15.94%
Open
2.82
Prev close
3.20
Mkt cap
36.87M
Vol
100.56K
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
2.82
High
3.20
Forward P/E
-1.27
Beta
0.00
Short ratio
2.59
Inst. own
50.60%
Dividend
0.00
Ex-div date
Earnings
Mar 29, 2024
50-d avg
2.73
200-d avg
2.89
1y target
4.13

2Y chart

Chart tools
Interval

Events in this range
  • Jul 25, 2023Split: 1 for 20
  • Aug 10, 2023Earnings: -1.07; estimate -2.6; surprise 58.85%
  • Nov 9, 2023Earnings: -0.57; estimate -1.52; surprise 62.5%
  • Nov 13, 2023Rating: Piper Sandler · Neutral → Neutral
  • Apr 15, 2024Rating: Benchmark · Speculative Buy → Speculative Buy
  • Apr 17, 2024Rating: Stephens & Co. · Equal-Weight → Equal-Weight
  • Apr 24, 2024Rating: Needham · Buy → Buy
  • May 15, 2024Earnings: -1.13; estimate 0; surprise —%
  • May 16, 2024Rating: Needham · Buy → Buy
  • Aug 8, 2024Earnings: -0.36; estimate 0; surprise —%
  • Aug 9, 2024Rating: Needham · Buy → Buy
  • Nov 12, 2024Earnings: -0.98; estimate 0; surprise —%
Signals (118)
NameDateAgo
SMA: BearishJun 9, 20251 year ago
SMA: BearishJun 4, 20251 year ago
MACD: Sell SignalJun 4, 20251 year ago
MACD: Buy SignalMay 21, 20251 year ago
SMA: BullishMay 20, 20251 year ago
SMA: BearishMay 12, 20251 year ago
SMA: BearishMay 7, 20251 year ago
MACD: Sell SignalMay 6, 20251 year ago
SMA: BearishApr 29, 20251 year ago
SMA: BullishApr 24, 20251 year ago
MACD: Buy SignalApr 23, 20251 year ago
SMA: BullishApr 21, 20251 year ago
SMA: BearishApr 16, 20251 year ago
SMA: BearishApr 11, 20251 year ago
SMA: BearishApr 10, 20251 year ago
SMA: BullishApr 9, 20251 year ago
SMA: BullishApr 9, 20251 year ago
SMA: BearishApr 4, 20251 year ago
SMA: BearishApr 4, 20251 year ago
MACD: Sell SignalMar 19, 20251 year ago
RSI: OverboughtMar 4, 20251 year ago
SMA: BullishFeb 28, 20251 year ago
RSI: OverboughtFeb 19, 20251 year ago
SMA: BullishFeb 11, 20251 year ago
MACD: Buy SignalJan 30, 20251 year ago
MACD: Sell SignalJan 17, 20251 year ago
MACD: Buy SignalDec 30, 20241 year ago
RSI: OversoldDec 20, 20241 year ago
RSI: OversoldDec 17, 20241 year ago
MACD: Sell SignalDec 16, 20241 year ago
MACD: Buy SignalDec 10, 20241 year ago
RSI: OversoldDec 5, 20241 year ago
RSI: OversoldNov 19, 20241 year ago
SMA: BearishNov 13, 20241 year ago
SMA: BullishNov 12, 20241 year ago
SMA: BearishNov 4, 20241 year ago
SMA: BearishOct 30, 20242 years ago
MACD: Sell SignalOct 30, 20242 years ago
SMA: BullishOct 28, 20242 years ago
SMA: BearishOct 24, 20242 years ago
SMA: BullishOct 14, 20242 years ago
SMA: BearishOct 11, 20242 years ago
SMA: BullishOct 9, 20242 years ago
MACD: Buy SignalOct 8, 20242 years ago
SMA: BullishOct 7, 20242 years ago
SMA: BearishOct 4, 20242 years ago
SMA: BullishOct 1, 20242 years ago
SMA: BearishSep 25, 20242 years ago
SMA: BearishSep 24, 20242 years ago
MACD: Sell SignalSep 24, 20242 years ago
SMA: BullishSep 20, 20242 years ago
MACD: Buy SignalSep 20, 20242 years ago
SMA: BullishSep 19, 20242 years ago
SMA: BearishSep 18, 20242 years ago
SMA: BearishSep 17, 20242 years ago
SMA: BullishSep 16, 20242 years ago
MACD: Sell SignalSep 12, 20242 years ago
SMA: BearishSep 11, 20242 years ago
SMA: BullishSep 6, 20242 years ago
MACD: Buy SignalSep 6, 20242 years ago
SMA: BearishSep 5, 20242 years ago
MACD: Sell SignalSep 5, 20242 years ago
SMA: BullishAug 29, 20242 years ago
MACD: Buy SignalAug 29, 20242 years ago
SMA: BearishAug 28, 20242 years ago
MACD: Sell SignalAug 28, 20242 years ago
MACD: Buy SignalAug 22, 20242 years ago
SMA: BullishAug 16, 20242 years ago
SMA: BullishAug 16, 20242 years ago
SMA: BearishAug 15, 20242 years ago
SMA: BearishAug 15, 20242 years ago
SMA: BullishAug 13, 20242 years ago
SMA: BullishAug 13, 20242 years ago
SMA: BearishAug 12, 20242 years ago
SMA: BearishAug 12, 20242 years ago
SMA: BullishAug 6, 20242 years ago
SMA: BullishAug 6, 20242 years ago
SMA: BearishAug 5, 20242 years ago
SMA: BearishAug 2, 20242 years ago
MACD: Sell SignalJul 30, 20242 years ago
MACD: Buy SignalJul 25, 20242 years ago
MACD: Sell SignalJul 24, 20242 years ago
RSI: OverboughtJul 12, 20242 years ago
SMA: BullishJul 3, 20242 years ago
SMA: BullishJun 27, 20242 years ago
MACD: Buy SignalJun 27, 20242 years ago
MACD: Sell SignalJun 25, 20242 years ago
SMA: BearishJun 24, 20242 years ago
SMA: BullishJun 20, 20242 years ago
SMA: BearishJun 18, 20242 years ago
MACD: Buy SignalJun 14, 20242 years ago
SMA: BearishMay 28, 20242 years ago
MACD: Sell SignalMay 28, 20242 years ago
SMA: BearishMay 20, 20242 years ago
SMA: BullishMay 9, 20242 years ago
MACD: Buy SignalMay 2, 20242 years ago
RSI: OversoldApr 15, 20242 years ago
MACD: Sell SignalMar 28, 20242 years ago
SMA: BearishMar 25, 20242 years ago
SMA: BullishMar 22, 20242 years ago
SMA: BullishFeb 20, 20242 years ago
MACD: Buy SignalFeb 16, 20242 years ago
MACD: Sell SignalJan 25, 20242 years ago
SMA: BearishJan 22, 20242 years ago
MACD: Buy SignalJan 3, 20242 years ago
SMA: BullishJan 2, 20242 years ago
SMA: BearishDec 8, 20232 years ago
MACD: Sell SignalDec 5, 20232 years ago
RSI: OverboughtNov 24, 20232 years ago
RSI: OverboughtNov 15, 20232 years ago
SMA: BullishNov 14, 20232 years ago
MACD: Buy SignalNov 9, 20232 years ago
RSI: OversoldOct 23, 20233 years ago
MACD: Sell SignalOct 19, 20233 years ago
MACD: Buy SignalSep 18, 20233 years ago
MACD: Sell SignalSep 15, 20233 years ago
MACD: Buy SignalAug 23, 20233 years ago
RSI: OversoldAug 15, 20233 years ago

Key statistics

Market cap
36.87M
Enterprise value
30.66M
Trailing P/E
0.00
Forward P/E
-1.27
PEG ratio
0.00
Price / sales
52.00
Price / book
3.09
EPS (TTM)
-4.44
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
709.00K
Revenue growth
-73.20%
Free cash flow
-7.61M
Total cash
3.36M
Total debt
3.99M
Return on equity
-165.32%
Shares outstanding
16.84M
Short % of float
1.88%
50-day average
2.73
200-day average
2.89

Analyst view

Consensus: none

Price target (mean) 4.13 +28.9% upside
Target (low)
4.00
Target (mean)
4.13
Target (high)
4.25
Ratings (0m) 3 1 buy · 2 hold · 0 sell
  • Strong buy1
  • Buy0
  • Hold2
  • Sell0
  • Strong sell0

Next earnings

Mar 29, 2024

Expected Mar 29, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
OCX Revenue — quarterly 2.14M
2021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 2025
OCX Net income — quarterly -6.67M
2021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 2025
OCX EPS — quarterly -0.26
2021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 2025

Earnings

OCX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 20240.00-0.98——
Aug 8, 2024Jun 1, 20240.00-0.36——
May 15, 2024Mar 1, 20240.00-1.13——
Mar 29, 2024Dec 1, 2023-1.57———
Nov 9, 2023Sep 1, 2023-1.52-0.57+0.95+62.50%
Aug 10, 2023Jun 1, 2023-2.60-1.07+1.53+58.85%

Upgrades / downgrades

OCX analyst upgrades and downgrades
DateFirmActionFromTo
Aug 9, 2024NeedhamreitBuyBuy
May 16, 2024NeedhamreitBuyBuy
Apr 24, 2024NeedhammainBuyBuy
Apr 17, 2024Stephens & Co.reitEqual-WeightEqual-Weight
Apr 15, 2024BenchmarkreitSpeculative BuySpeculative Buy
Nov 13, 2023Piper SandlermainNeutralNeutral

About OncoCyte Corporation

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
oncocyte.com

News

Your note

Sign in to keep a note on OCX — it syncs with the Stock Master app.

Insider holders

OCX insider holders
InsiderRelationLatest transactionDateShares held
ARNO ANDREWDirectorPurchaseApr 10, 202484,662
BROADWOOD PARTNERS, L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseOct 1, 20240
GUTFREUND JOHN PETERDirectorStock Award(Grant)Apr 2, 20230
JAMES ANDREA S.Chief Financial OfficerPurchaseDec 4, 202453,670
KINGSLEY ALFRED DDirectorStock Award(Grant)Jun 22, 2023583,223
LAST ANDREW JDirectorStock Award(Grant)Jun 22, 202390,170

Institution ownership

OCX institution ownership
Holder% heldSharesValueReported
Broadwood Capital, Inc.29.28%4,929,06610.79MSep 29, 2024
AWM Investment Company, Inc.6.52%1,097,1752.40MSep 29, 2024
Pura Vida Investments, Llc2.94%495,3451.08MSep 29, 2024
Vanguard Group Inc1.46%245,388537.40KSep 29, 2024
Geode Capital Management, LLC0.62%103,980227.72KSep 29, 2024
Blackrock Inc.0.47%79,833174.83KSep 29, 2024

Fund ownership

OCX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund0.92%154,885339.20KSep 29, 2024
Vanguard Extended Market Index Fund0.50%84,999186.15KSep 29, 2024
Fidelity Extended Market Index Fund0.40%67,344147.48KOct 30, 2024
iShares Micro Cap ETF0.11%18,03239.49KOct 30, 2024
Fidelity Series Total Market Index Fund0.09%14,75632.31KOct 30, 2024
Fidelity Total Market Index Fund0.08%13,83630.30KOct 30, 2024
Advertisement